OCGN - NASDAQ
Ocugen, Inc.
$1.30
-5.1%Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
At a Glance
Live SnapshotOcugen, Inc. Management Team
Ms. Tiffany J. Hamilton M.B.A.
AVice President & Head of Corporate Communications
Mr. Ramesh Ramachandran C.M.A., CPA, M.B.A.
Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer
Dr. Huma Qamar CMI, M.D., M.P.H.
Chief Medical Officer
Compensation
$602,737
Dr. Arun Upadhyay Ph.D.
Chief Scientific Officer and Head of Research & Development
Compensation
$649,630
Dr. Shankar Musunuri M.B.A., Ph.D.
Co-Founder, Chief Executive Officer & Chairman
Compensation
$1,151,298
Dr. Uday B. Kompella Ph.D.
Co-founder & Independent Director
Compensation
$61,875
John Kouch J.D.
General Counsel
Ms. Kristen Craft
Head of People & Culture
Mr. Michael Shine M.B.A.
Senior Vice President of Commercial
Ms. Jyothy Pillai M.S.
Vice President & Head of Regulatory & Quality
Ocugen, Inc. Insider Positioning
During the last 12 months, insiders have sold $56K worth of OCGN shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
25.0K
55.50K
-56K
-$56K
Top Buyers
No buying activity
Top Sellers
Chandrasekhar Satishchandran
Director
$56K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $56K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
OCGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 11, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 28, 2024 | June 28, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 20, 2023 | June 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 11, 2021 | 2021 | |
DEF 14A DEF 14A 2021 N/A | February 22, 2021 | March 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | October 30, 2020 | December 11, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | November 08, 2019 | December 18, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2018 | June 15, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.